Clinical trials: Malaria,Falciparum, open to volunteers
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria (Plasmodium Falciparum), Malaria Incidence
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings
- Trial name
- NCT07903324
- Testing
- Factory-treated lesu, Soaked lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria,Falciparum
Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)
This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected…
- Trial name
- NCT06293339
- Testing
- CHMI with 3D7 malaria
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Malaria (Plasmodium Falciparum)
Malaria CVD 36000; Gates INV090205
In order to control infections, the investigators must first detect them. Biosensor devices may allow early detection and intervention for infectious diseases, helping the investigators to recognize infections early, and allow…
- Trial name
- NCT07558122
- Testing
- PfSPZ Challenge (NF54), Wearable Biosensor Devices
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria,Falciparum
Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.
The investigators believe that to effectively achieve malaria elimination in Rwanda, it is critical to target the human reservoirs of Plasmodium falciparum using local and readily available Artemisia tea.
- Trial name
- NCT05801198
- Testing
- Artemisia afra or Annua 10g oral infusion/tea per day for 14 days
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- King Faisal Hospital Rwanda
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Asymptomatic Malaria
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Malaria remains a major cause of illness among school-aged children in sub-Saharan Africa, many of whom carry asymptomatic Plasmodium falciparum infections that may contribute to anemia, inflammation, school absenteeism, and…
- Conditions
- Malaria, Asymptomatic Malaria, Intermittent Preventive Treatment
- Trial name
- Optimal LEAP (NCT07798583)
- Testing
- Monthly DP, Quarterly DP
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Malaria
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
This is a single centre, randomized, placebo-controlled phase 1/2 study comparing two malaria vaccine candidates. The first vaccine candidate PfSPZ-CVac (Plasmodium falciparum sporozoites (PfSPZ) challenge administered with a…
- Trial name
- NCT05441410
- Testing
- Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors.
- Trial name
- WinMal (NCT07912528)
- Testing
- Spatial emanator outdoor, Spatial emanator indoor
- Where
- Papua New Guinea
- Volunteers
- 4,350 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria Falciparum, Malaria Infection
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
The goal of this clinical trial is to learn if the genetically-modified malaria parasite NF54/iGP3 will safely infect humans with malaria.
- Conditions
- Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- iGP3-SWITCH (NCT06881732)
- Testing
- NF54/iGP3
- Where
- Australia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Malaria (Plasmodium Falciparum), Malaria Incidence
Insecticide-Treated Baby Wraps for the Prevention of Malaria
The objective is to test the protective effect of permethrin-treated and etofenprox-treated lesus against malaria in young children
- Trial name
- NCT07773350
- Testing
- Permethrin-treated lesu, Etofenprox-treated lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria (Plasmodium Falciparum), Malaria Falciparum
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda.
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Falciparum, Malaria Infection, Malaria Prophylaxis
- Trial name
- NCT07548021
- Testing
- MMV371
- Where
- Rwanda
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Falciparum
Perennial Malaria Chemoprevention in the Malaria Vaccine Era
Malaria remains a major cause of pediatric deaths and morbidity in Africa. An affordable malaria vaccine, R21, is being deployed in Uganda and other African countries with high malaria transmission, but efficacy is incomplete and…
- Trial name
- PMC-VAC (NCT07322068)
- Testing
- Sulfadoxine pyrimethamine + Amodiaquine, Dihydroartemisinin Piperaquine
- Where
- Uganda
- Volunteers
- 1,290 people, healthy volunteers welcome
- Sponsor
- Stanford University
Plasmodium Falciparum Malaria, Malaria
R21/MM Dosing, Presentations, and Preservatives
This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults.
- Conditions
- Plasmodium Falciparum Malaria, Malaria, Vaccine Reaction
- Trial name
- VAC100 (NCT07194668)
- Testing
- 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative
- Where
- 2 sites in Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum, Morality
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are…
- Trial name
- NCT07009847
- Testing
- Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
- Where
- 5 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 2,308 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria Asymptomatic Parasitaemia, Malaria Falciparum
Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections.
- Conditions
- Malaria Asymptomatic Parasitaemia, Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- NCT07389057
- Testing
- DHAP, Single low dose PQ
- Where
- Ghana
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Malaria, Falciparum
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of…
- Trial name
- NCT07011511
- Testing
- MMV055 Dose 1, MMV055 Dose 2, MMV055 Dose 3
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture